Last reviewed · How we verify
MACIMORELIN ACETATE
At a glance
| Generic name | MACIMORELIN ACETATE |
|---|---|
| Drug class | Growth Hormone Secretagogue Receptor Agonist [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2017 |
Approved indications
Common side effects
- Dysgeusia
- Dizziness
- Headache
- Fatigue
- Nausea
- Hunger
- Diarrhea
- Upper respiratory tract infection
- Feeling hot
- Hyperhidrosis
- Nasopharyngitis
- Sinus bradycardia
Key clinical trials
- A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is (PHASE3)
- Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia (PHASE2)
- Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers (NA)
- Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test. (PHASE3)
- Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency (PHASE3)
- Oral Ghrelin Agonist in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MACIMORELIN ACETATE CI brief — competitive landscape report
- MACIMORELIN ACETATE updates RSS · CI watch RSS